On Wednesday, Shares of United Continental Holdings Inc (NYSE:UAL), lost -3.05% to $57.49.
Readers of Global Traveler voted United’s MileagePlus loyalty program the Best Overall Frequent-Flyer Program in the world for 2015, marking the twelfth successive year that MileagePlus has received the award. Global Traveler readers who took part in the 2015 GT Tested Reader Survey bestowed United with the honor, affirming MileagePlus’ position as the industry’s leading loyalty program.
Global Traveler readers also selected United as the Best Trans-Pacific Airline and, for the second straight year, named MileagePlus the Best Frequent-Flyer Bonus Program. Thomas F. O’Toole, United’s senior vice president, chief marketing officer and president of MileagePlus, accepted the honors at the annual Global Traveler awards dinner in Beverly Hills, California, earlier this month.
“The 2015 Global Traveler awards, voted on by savvy travelers worldwide, recognize our ongoing commitment to advancing United’s service to our customers,” said O’Toole. “We are particularly gratified that readers voted MileagePlus as the Best Overall Frequent-Flyer Program in the world for the twelfth successive year, which attests to our continued development of the industry’s top loyalty program.”
United Continental Holdings, Inc., together with its auxiliaries, provides air transportation services in North America, the Asia-Pacific, Europe, the Middle East, Africa, and Latin America. It transports people and cargo through its mainline operations, which use jet aircraft with about 118 seats, and its regional operations.
Shares of Baxter International Inc (NYSE:BAX), declined -1.35% to $38.04, during its last trading session.
Baxter International Inc. (BAX) declared that it will present at the 36th Annual JP Morgan Healthcare Conference on Monday, January 11, 2016 at 6:00 p.m. (CT).
Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company’s BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; and biosurgery products.
Finally, Inventergy Global Inc (NASDAQ:INVT), ended its last trade with -13.89% loss, and closed at $1.86.
On Wednesday, December 23, 2015, Nasdaq Composite ended at 5,045.93, up 0.90%, Dow Jones Industrial Average advanced 1.06%, to finish the day at 17,602.61, and the S&P 500 closed at 2,064.29, up 1.24%.
The stock of Inventergy Global Inc. gained 2.88% to close Wednesday’s session at USD 1.43. The shares of the company moved in the range of USD 1.34 and USD 1.48. A trading volume of 0.08 million shares was recorded, which was lower than its 150-day daily average volume of 0.13 million shares and its 52-week average volume of 0.09 million shares. Over the last five days Inventergy Global Inc.’s shares have declined by 21.43% while in the past one month the stock has gained a momentum of 2.14%. Additionally, over the last three months the stock has declined 63.43% and in the past six months the shares have registered a loss of 58.91%. The stock is having a 52-week range of USD 0.71 - USD 9.40. Moreover, the stock is trading 8.40% below its 20-day simple moving average and 57.13% below its 200-day simple moving average.
Inventergy Global, Inc. operates as an intellectual property (IP) investment and licensing company. The company identifies, acquires, and licenses the patented technologies of technology companies. It offers a professional corporate licensing model for IP value creation that provides short term returns and long-term licensing revenue.
